In vitro diagnostics (IVD) is the technique in which medical devices and reagents are used to examine specimens such as blood, urine, stool, tissues, and other body fluids of human body for detection of diseases, conditions, and infections; in an in-vitro environment.
The Asia-Pacific IVD market is driven by rise in geriatric population and rapid expansion of government healthcare expenditure. In addition, increase in awareness of personalized medicine and preventive healthcare measures boost the market share. Furthermore, rise in prevalence of communicable and non-communicable diseases are anticipated to increase the demand of diagnosis, thereby increasing the market growth. However, stringent
government regulations associated with the safety and efficacy of IVD products is expected to hinder the growth of the market during the forecast period. The emerging economies of the Asia-Pacific regions offer lucrative growth opportunities to IVD during the forecast period. The Asia-Pacific IVD market accounted for $13,680 million in 2016, and is estimated to reach at $19,888 million by 2023, growing at a CAGR of 5.4% from 2017-2023.
The market is segmented on the basis of product type, techniques, application, end-user, and country. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of techniques, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study include infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end-user, it is classified into, hospitals, academic and medical schools, point of care testing, and others. Country-wise, it is analyzed across India, China, Japan, South Korea, Australia, and Rest of Asia-Pacific.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the Asia-Pacific IVD market, with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
Reagents
Instruments
Software and Services
By Techniques
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques
By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications
By End Users
Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others
By Country
Japan
China
India
South Korea
Australia
Rest of Asia-Pacific
List of players profiled in the report
Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
